跳至主要内容
临床试验/NCT02624271
NCT02624271已完成不适用

Non Invasive Diagnosis of Gastric Precancerous Lesions by GastroPanel Blood Test in Patients With Increased Gastric Cancer Risk : a French Multicenter Study

Nantes University Hospital2 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2016年8月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
2,000
试验地点
2
主要终点
Sensitivity of GastroPanel blood test

研究概览

简要总结

Despite the declining incidence, gastric cancer (GC) remains the second leading cause of cancer death worldwide. In France, it is the second digestive cancer with 7,000 new cases per year. It is now well demonstrated that patients with H. pylori infection, atrophic gastritis and intestinal metaplasia, have a high risk of developing GC. It is therefore important to detect these pre-neoplastic lesions at an early stage to improve patients prognosis.

Thus, the aim of this project is to investigate the possible screening of gastric precancerous lesions by a blood test (GastroPanel®) in France, in patients with oesophagogastroduodenoscopy (EGD) prescription.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients undergoing oesophagogastroduodenoscopy (EGD) according to usual care
  • Patients with increased risk of gastric cancer (at least one of the following criteria):
  • age > 50 years,
  • family cases of gastric cancer,
  • known precancerous lesions,
  • Biermer disease,
  • H. Pylori infection,
  • genetic predisposition (ex: Lynch syndrome),
  • MALT lymphoma,
  • dyspepsia.
  • Subjects affiliated with an appropriate social security system

排除标准

  • Subjects with known active cancer
  • Pregnancy
  • Patients receiving proton-pump inhibitors
  • Conditions that may interfere with the study objectives according to the investigator

结局指标

主要结局

Sensitivity of GastroPanel blood test

时间窗: One assessment at baseline

The pepsinogen I (PGI) level measure will be compared with the gold standard method (anatomopathological examination of gastric biopsy). Results will be expressed in accordance with Sydney system. Patients will be classified as ill if PGI\<30µg/l, healthy if PGI \>=30µg/l. The sensitivity of GastroPanel test will be calculated with their 95% confidence interval.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Diagnosis of Gastric Precancerous Lesions by a Blood... | 临床试验